A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial

What Was Tested

The paper reports a study of Insulin Glargine and Insulin Aspart, published as a randomized controlled trial.

Insulin degludec coformulated with insulin aspart (as IDegAsp) can cover 24 h basal insulin and postprandial insulin requirements after a main meal with one injection.

The researchers compared glycemic stability following IDegAsp or insulin glargine (IGlar) given before the evening meal in patients with type 2 diabetes.

Who Took Part

According to the abstract, 2 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

A subset of 112 insulin-naïve type 2 diabetes patients from a randomized, parallel-group trial (IDegAsp versus IGlar, each added to metformin) underwent 72 h continuous interstitial glucose (IG) monitoring after 16 weeks of treatment.

How the Study Was Run

The design is described as randomized and parallel-group.

The patients were allocated by chance, so the Insulin Glargine group and the comparison group should start out alike.

The Insulin Glargine group and the comparison group ran side by side rather than switching.

The timeline in the abstract includes 16 weeks.

Values were derived for the entire 72 h, with the nocturnal interval (0001-0559 h) also assessed.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin Aspart, Insulin, Long-Acting and Postprandial Period.

What This Means in Plain Language

The paper is a randomized and parallel-group study of Insulin Glargine and Insulin Aspart in 2 patients over 16 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2013 (Journal of diabetes science and technology), a journal based in United States.

More context: the Insulin Glargine compound page and the Insulin Aspart compound page.